Caris Life Sciences (NASDAQ:CAI) Coverage Initiated by Analysts at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $27.00 price objective on the stock.

Several other research analysts have also weighed in on the company. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Robert W. Baird upped their price target on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Evercore set a $38.00 price objective on Caris Life Sciences in a report on Monday, January 5th. Canaccord Genuity Group reduced their price objective on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. Finally, BTIG Research decreased their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 27th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Caris Life Sciences has a consensus rating of “Hold” and an average price target of $30.60.

Caris Life Sciences Stock Performance

Shares of CAI stock opened at $19.13 on Wednesday. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $5.41 billion and a price-to-earnings ratio of -106.28. Caris Life Sciences has a one year low of $16.28 and a one year high of $42.50. The stock’s 50 day moving average is $20.43.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. During the same quarter last year, the business earned ($1.73) EPS. The firm’s revenue for the quarter was up 125.4% compared to the same quarter last year.

Institutional Trading of Caris Life Sciences

Several large investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its stake in shares of Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after purchasing an additional 1,180,200 shares in the last quarter. Braidwell LP grew its stake in shares of Caris Life Sciences by 6.8% in the fourth quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after buying an additional 500,000 shares in the last quarter. PointState Capital LP grew its stake in shares of Caris Life Sciences by 73.0% in the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after buying an additional 2,834,986 shares in the last quarter. Orbimed Advisors LLC raised its holdings in shares of Caris Life Sciences by 2.7% during the 4th quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock valued at $84,070,000 after buying an additional 81,153 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Caris Life Sciences by 185.0% during the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after acquiring an additional 1,587,176 shares in the last quarter.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.